Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27359921 | 0.81 | DGAT1 (0.35) | CYP4F2CYP4A11ACLY | |
| SCHEMBL29471555 | 0.79 | DGAT1 (0.39) | CYP4F2CYP4A11ACLY | |
| SCHEMBL11070452 | 0.78 | CYP4F2 (0.55) | CYP4F2CYP4A11 | |
| SCHEMBL9052102 | 0.76 | TDP1 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL7298507 | 0.76 | ACLY (0.33) | ACLY | |
| SCHEMBL24572029 | 0.73 | ACLY (0.34) | ACLY | |
| SCHEMBL27582201 | 0.73 | GAA (0.34) | ACLY | |
| SCHEMBL1012581 | 0.73 | ACLY (0.54) | ACLY | |
| SCHEMBL7299411 | 0.71 | ACLY (0.33) | ACLY | |
| SCHEMBL6634478 | 0.71 | ACLY (0.33) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |